Contineum Therapeutics, Inc. (CTNM) Return on equity
Contineum Therapeutics, Inc. (CTNM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-21.3%FY2024
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -21.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CTNM financial trends
CTNM RevenueCTNM Net incomeCTNM Net marginCTNM Gross profitCTNM Gross marginCTNM Operating incomeCTNM Operating marginCTNM Operating cash flowCTNM Free cash flowCTNM Capital expendituresCTNM Stock buybacksCTNM Dividends paidCTNM Total assetsCTNM Total liabilitiesCTNM Shareholders’ equityCTNM overview →